Insider · CIK 0002031699
John Prosper Mack
Files at OBIO (Orchestra BioMed Holdings, Inc.). First filing -, latest -.
John Prosper Mack files SEC Form 4 as director at OBIO (Orchestra BioMed Holdings, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; John Prosper Mack has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 7, 2025 | OBIO Orchestra BioMed Holdings, Inc. | AGrant or award Common Stock, par value $0.0001 per share ("Common Stock") | +15,000 | $0.00 | $0 | 40,286 | Aug 8, 2025 |
| Jun 24, 2025 | OBIO Orchestra BioMed Holdings, Inc. | AGrant or award Common Stock, par value $0.0001 per share ("Common Stock") | +12,422 | $0.00 | $0 | 25,286 | Jun 26, 2025 |
| Jun 24, 2025 | OBIO Orchestra BioMed Holdings, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +36,797 | $0.00 | $0 | 36,797 | Jun 26, 2025 |
Questions about John Prosper Mack
Answered from the filings on this page, as of the latest one.
Is John Prosper Mack buying or selling?
John Prosper Mack has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did John Prosper Mack's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and John Prosper Mack has 0.
Where does John Prosper Mack file Form 4?
John Prosper Mack has filed Form 4 at OBIO (Orchestra BioMed Holdings, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.